Transforming biomedical data
into better outcomes for everyone

Welcome to Molecular Health!

History

Since 2004, Molecular Health has stood for transforming big data into precise, actionable decisions for all stakeholders in healthcare. Our cloud-based Dataome® technology platform analyzes the molecular and clinical data of individual patients against the world’s medical, biological, and pharmacological knowledge, to drive more precise diagnostic, therapeutic, and drug safety decisions.

Our products are used across the healthcare sector, as more precise ways of practicing medicine impact the treatment of patients and the development of effective drugs, requiring ever more complex levels of data interpretation.

The company is financed by Dievini Hopp BioTech, an investment vehicle of former SAP CEO and founder Dietmar Hopp.

Join our team!


Our solutions are only as smart as the people behind them. This is why we are always looking for motivated employees from a variety of different fields and many different backgrounds. – Come work for and with us on the digital health of today and tomorrow!

Vacancies

Leadership

Molecular Health is run by a team of oncologists, scientists, technologists and Entrepreneurs with long-time experience in any field of oncology, bioinformatics and biomedicine.

Board of Directors

Prof. Dr.
Christof Hettich, PhD


Christof Hettich is a lawyer and partner at RITTERSHAUS Rechtsanwälte in Mannheim/Frankfurt/Munich and is also the co-founder and managing director of dievini Hopp BioTech holding GmbH & Co. KG.

Dr.
Mathias Hothum, PhD


Mathias Hothum, owner of HMM-Consulting, received a degree in Economics from the University of Mannheim. He completed his doctoral studies at the University of Magdeburg

Dr.
Alexander Schuth, MD


Alexander Schuth is co-founder and COO of Denali Therapeutics, a San Francisco based biotech company dedicated to the discovery and development of therapies for neurodegenerative diseases. He holds an M.B.A. from the Wharton School and an M.D. from the Charite Medical School at the Humboldt University.

Management Team

“I am driven by the difference we can make – and are making – for patients, for caregivers and for innovators pushing the boundaries of what’s possible in medicine.”


Dr. Friedrich von Bohlen und Halbach, Chief Executive Officer

Dr. Stephan Brock


Chief Technology Officer

Dr. Rudolf Caspary


Chief Information Officer

Dr. David Jackson


Chief Innovation Officer

Dr. Christian Meisel


Chief Medical Officer

Blanca Baez


SVP, Global Head of Pharma & Biotech

Stephan Hettich


SVP, Head of Business Development,
Sales and Marketing EMEA/APAC

Dr. Niels Bojunga


SVP Quality Management

Thorsten Vogt


Head of HR

Michael Ghaffar


General Counsel

Torsten Bürgermeister


SVP Finance & Administration

Certified quality and patient-data privacy

Molecular Health Guide® (MH Guide) is registered in Europe as an in-vitro diagnostic medical device. It goes without saying that the services Molecular Health offers fulfill the strict requirements of the Federal Data Protection Act (BDSG) and the German Genetic Diagnostic Act (GenDG).

CLIA-CERTIFIED


Molecular Health is certified in compliance with the quality standards of the US Clinical Laboratory Improvement Amendments (CLIA), which are issued by the US federal agency Centers for Medicare and Medicaid Services (CMS).

DOWNLOAD

CAP-ACCREDITED


Molecular Health has been accredited by the College of American Pathologists (CAP), which means it complies with US laboratory standards to ensure the proper validity, handling and reporting of dry-laboratory results.

DOWNLOAD

DIN EN ISO 13485


Molecular Health GmbH is DIN EN ISO 13485 certified for the scope Design, Development and Manufacture of software systems for the integrated analysis of clinical and genomic patient data to support treatment decisions and provisioning of related services.

DOWNLOAD

Investors

Molecular Health was founded in 2004, and since then it has stood for transforming big data into precise, actionable decisions for all stakeholders in healthcare.

The company is financed by Dievini Hopp BioTech, an investment vehicle of former SAP CEO and founder Dietmar Hopp.

Dievini

Dievini is an active investor in life and health sciences companies. The company is dedicated to advancing innovative therapeutic and diagnostic technologies to establish novel treatment regimens for life-threatening diseases. Established by Dietmar Hopp, founder and former Chairman and CEO of SAP, the company maintains deep roots in the health and technology sectors and is led by a team with an extensive track record of building scalable, sustainable life science and health technology companies.